Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 study of CC-90011 in combination with nivolumab in advanced lung cancers
2019-004194-95Phase 2Completed
- Sponsor
- Celgene Corporation
- Start
- Jan 2020
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of pulrodemstat and nivolumab in small cell lung cancer (SCLC) and Pulmonary squamous cell carcinoma, sponsored by Celgene Corporation. Primary endpoint: Overall response rate. Started Jan 2020; status: completed.
02
Drugs
pulrodemstatnivolumab
03
Conditions
small cell lung cancer (SCLC)Pulmonary squamous cell carcinoma
Beyond the preview
Go deeper on 2019-004194-95.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-004194-95.